Pacira BioSciences Past Earnings Performance
Past criteria checks 3/6
Pacira BioSciences has been growing earnings at an average annual rate of 0.03%, while the Pharmaceuticals industry saw earnings growing at 0.03% annually. Revenues have been growing at an average rate of 14.1% per year. Pacira BioSciences's return on equity is 7.9%, and it has net margins of 10.3%.
Key information
0.03%
Earnings growth rate
-1.1%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 14.1% |
Return on equity | 7.9% |
Net Margin | 10.3% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Safely
Jun 07Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
May 10Getting In Cheap On Pacira BioSciences, Inc. (NASDAQ:PCRX) Might Be Difficult
May 03Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?
Feb 05Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement
Jan 05We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt
Nov 03Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?
Jul 28Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price
Jul 07Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?
Apr 18We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt
Dec 28Assessing Pacira BioSciences' Growth Prospects
Oct 20Pacira BioSciences guides Q3 revenue below consensus
Oct 13Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures
Sep 27EMA panel backs expanding indication for Pacira's postsurgical pain treatment in kids
Sep 20Pacira BioSciences records 17.7% sequential growth in August revenue
Sep 13Pacira BioSciences provides update on July product sales
Aug 10Pacira BioSciences Q2 2022 Earnings Preview
Aug 02Pacira BioSciences sees Q2 revenue below consensus
Jul 14These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Reasonably Well
Apr 04Pacira BioSciences: Higher Prices On The Horizon
Dec 20Investors Appear Satisfied With Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Prospects
Nov 29Pacira BioSciences (NASDAQ:PCRX) Seems To Use Debt Rather Sparingly
Oct 15Revenue & Expenses Breakdown
How Pacira BioSciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 682 | 70 | 271 | 0 |
31 Dec 23 | 675 | 42 | 269 | 0 |
30 Sep 23 | 666 | 7 | 268 | 0 |
30 Jun 23 | 669 | -5 | 261 | 0 |
31 Mar 23 | 669 | -10 | 261 | 0 |
31 Dec 22 | 667 | 16 | 255 | 0 |
30 Sep 22 | 654 | 21 | 243 | 0 |
30 Jun 22 | 614 | 39 | 229 | 0 |
31 Mar 22 | 580 | 38 | 215 | 0 |
31 Dec 21 | 542 | 42 | 199 | 0 |
30 Sep 21 | 513 | 62 | 200 | 0 |
30 Jun 21 | 503 | 174 | 205 | 0 |
31 Mar 21 | 443 | 148 | 197 | 0 |
31 Dec 20 | 430 | 146 | 194 | 0 |
30 Sep 20 | 421 | 126 | 197 | 0 |
30 Jun 20 | 408 | -10 | 195 | 0 |
31 Mar 20 | 435 | 0 | 200 | 0 |
31 Dec 19 | 421 | -11 | 201 | 0 |
30 Sep 19 | 394 | 2 | 191 | 0 |
30 Jun 19 | 372 | 8 | 185 | 0 |
31 Mar 19 | 354 | 7 | 180 | 0 |
31 Dec 18 | 337 | 0 | 177 | 0 |
30 Sep 18 | 321 | -4 | 172 | 0 |
30 Jun 18 | 305 | -11 | 168 | 0 |
31 Mar 18 | 292 | -33 | 164 | 0 |
31 Dec 17 | 287 | -43 | 161 | 0 |
30 Sep 17 | 280 | -51 | 157 | 0 |
30 Jun 17 | 281 | -66 | 153 | 0 |
31 Mar 17 | 280 | -54 | 157 | 0 |
31 Dec 16 | 276 | -38 | 153 | 0 |
30 Sep 16 | 273 | -36 | 155 | 0 |
30 Jun 16 | 267 | -11 | 154 | 0 |
31 Mar 16 | 256 | -3 | 146 | 0 |
31 Dec 15 | 249 | 2 | 139 | 0 |
30 Sep 15 | 241 | 10 | 133 | 0 |
30 Jun 15 | 231 | 4 | 125 | 0 |
31 Mar 15 | 219 | -1 | 116 | 0 |
31 Dec 14 | 198 | -14 | 107 | 0 |
30 Sep 14 | 169 | -31 | 96 | 0 |
30 Jun 14 | 141 | -43 | 83 | 0 |
31 Mar 14 | 111 | -52 | 72 | 0 |
31 Dec 13 | 86 | -64 | 63 | 22 |
30 Sep 13 | 62 | -68 | 56 | 0 |
30 Jun 13 | 48 | -69 | 52 | 0 |
Quality Earnings: PCRX has high quality earnings.
Growing Profit Margin: PCRX became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PCRX's earnings have grown by 0.03% per year over the past 5 years.
Accelerating Growth: PCRX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: PCRX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (15.5%).
Return on Equity
High ROE: PCRX's Return on Equity (7.9%) is considered low.